stilbenes and Ventricular-Fibrillation

stilbenes has been researched along with Ventricular-Fibrillation* in 6 studies

Other Studies

6 other study(ies) available for stilbenes and Ventricular-Fibrillation

ArticleYear
Piceatannol facilitates conduction block and ventricular fibrillation induction in ischemia-reperfused rabbit hearts with pacing-induced heart failure.
    International journal of cardiology, 2014, Feb-01, Volume: 171, Issue:2

    Piceatannol, a hydroxystilbene natural product, has been reported to exert antiarrhythmic action via INa inhibition and slow INa inactivation in ischemia-reperfused (IR) rat hearts. The present study aimed to clarify the proarrhythmic property of piceatannol during regional IR injury in failing rabbit hearts.. Heart failure (HF) was induced by rapid right ventricular pacing for 4 weeks. The IR model was created by coronary artery ligation for 30 min, followed by reperfusion for 15 min in vivo. Simultaneous voltage and intracellular Ca(2+) (Cai) optical mapping was then performed in isolated Langendorff-perfused hearts (n=11 in each HF and control group). Action potential duration (APD) restitution, arrhythmogenic alternans and VF inducibility were evaluated by a dynamic pacing protocol. Conduction velocity was measured along lines across the IR and non-IR zones during pacing. Piceatannol (10 μM) was administered after baseline studies.. In the HF group, piceatannol decreased conduction velocity, induced rate-dependent regional inhomogeneity of conduction delay and wavelength shortening, slowed Cai decay, and facilitated arrhythmogenic alternans instead of APD prolongation to increase VF inducibility. In the control group, the proarrhythmic effects of piceatannol on APD restitution, arrhythmogenic alternans and conduction delay were offset by its antiarrhythmic effects (APD and wavelength prolongation), resulting in a neutral effect on VF inducibility.. Piceatannol (10 μM) is proarrhythmic in failing rabbit hearts with regional IR injury. The increased VF inducibility by piceatannol in HF suggests that its undesirable effects are more pronounced than its benefits in failing hearts.

    Topics: Animals; Calcium; Disease Models, Animal; Electrophysiologic Techniques, Cardiac; Heart Block; Heart Conduction System; Heart Failure; Myocardial Reperfusion Injury; Perfusion; Protein-Tyrosine Kinases; Rabbits; Stilbenes; Ventricular Fibrillation

2014
Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction.
    Cardiovascular drugs and therapy, 2008, Volume: 22, Issue:6

    The effects of resveratrol treatment on ventricular arrhythmia, survival, and late cardiac remodeling were evaluated in rats with myocardial infarction (MI).. Three groups of rats (S: ham-operated, MI, and MI pre-treated with resveratrol) were treated in an in vivo MI model by ligation of left anterior descending coronary artery. The electrocardiogram signals were monitored and recorded for 24 h using an implanted telemetry transmitter. The incidence of ventricular arrhythmias during the first 24-h after MI was also evaluated. Meanwhile, invasive in vivo electrophysiology with pacing in the right ventricle was performed in each group to assess the inducibility of ventricular arrhythmias.. Administration of resveratrol significantly suppressed the MI-induced ventricular tachycardia and ventricular fibrillation (0.4 +/- 0.2 in Resv group vs. 7.1 +/- 2.2 in MI group episodes per hour per rat, P < 0.01). Data also showed that the incidence of inducible ventricular tachycardia was lower in the Resv group than the MI group (46% vs. 81%, P < 0.01). The infarct size and mortality in the Resv group at 14 weeks were reduced by 20% and 33%, respectively, compared with the MI groups. Results from patch clamp recording revealed that resveratrol inhibited L-type calcium current (I (Ca-L)), and selectively enhanced ATP-sensitive K(+) current (I (K,ATP)) in a concentration-dependent manner.. These results suggested that the emerging anti-arrhythmic character induced by resveratrol treatment in rat hearts could be mainly accounted for by inhibition of I (Ca-L) and enhancement of I (K,ATP). Administration of resveratrol also improved the long-term survival by suppressing left ventricular remodeling.

    Topics: Administration, Oral; Animals; Calcium Channels, L-Type; Cardiac Pacing, Artificial; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; KATP Channels; Male; Myocardial Infarction; Patch-Clamp Techniques; Phytoalexins; Prostheses and Implants; Rats; Rats, Sprague-Dawley; Resveratrol; Sesquiterpenes; Stilbenes; Survival Rate; Tachycardia, Ventricular; Telemetry; Terpenes; Time Factors; Ventricular Fibrillation; Ventricular Remodeling

2008
Cardioprotective and antiarrhythmic effects of resveratrol--a modern perspective on an old treatment: editorial to "resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction" by Chen et al.
    Cardiovascular drugs and therapy, 2008, Volume: 22, Issue:6

    Topics: Animals; Anti-Arrhythmia Agents; Cardiotonic Agents; Drug Therapy; Humans; Myocardial Infarction; Rats; Resveratrol; Stilbenes; Survival Rate; Time Factors; Ventricular Fibrillation; Ventricular Flutter

2008
Beneficial effects of astringinin, a resveratrol analogue, on the ischemia and reperfusion damage in rat heart.
    Free radical biology & medicine, 2001, Apr-15, Volume: 30, Issue:8

    Oxidative stress plays an important role in the pathogenesis of myocardial ischemia and infarction. Antioxidants might then be beneficial in the prevention of these diseases. Astringinin (3,3',4',5-tetrahydroxystilbene), a resveratrol (3,4',5-trihydroxystilbene) analogue with considerably higher antioxidative activity and free radical scavenging capacity, was introduced to examine its cardioprotective effects in ischemia or ischemia-reperfusion (I/R) rats. In the present study, the left main coronary artery was occluded by the following procedures: (i) 30 min occlusion, (ii) 5 min occlusion followed by 30 min reperfusion, and (iii) 4 h occlusion. Animals were infused with and without astringinin before coronary artery occlusion. Mortality, and the severity of ischemia- and I/R-induced arrhythmias were compared. Pretreatment of astringinin dramatically reduced the incidence and duration of ventricular tachycardia (VT) and ventricular fibrillation (VF) during either ischemia or I/R period. Astringinin at 2.5 x 10(-5) and 2.5 x 10(-4) g/kg completely prevented the mortality of animals during ischemia or I/R. During the same period, astringinin pretreatment also increased nitric oxide (NO) and decreased lactate dehydrogenase (LDH) levels in the carotid blood. In animals subjected to 4 h coronary occlusion, the cardiac infarct size (expressed as a percentage of occluded zone) was reduced from 44.4 + or - 4.1% to 19.1 + or - 2.4% by astringinin (2.5 x 10(-4) g/kg). We conclude that, astringinin is a potent antiarrhythmic agent with cardioprotective activity in ischemic and ischemic-reperfused rat heart. The beneficial effects of astringinin in the ischemic and ischemic-reperfused hearts may be correlated with its antioxidant activity and upregulation of NO production.

    Topics: Animals; Antioxidants; Free Radical Scavengers; Heart; Hemodynamics; L-Lactate Dehydrogenase; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitrates; Nitric Oxide; Nitrites; Rats; Resveratrol; Stilbenes; Tachycardia, Ventricular; Ventricular Fibrillation

2001
Benefits of resveratrol in women's health.
    Drugs under experimental and clinical research, 2001, Volume: 27, Issue:5-6

    Resveratrol and trans-resveratrol are powerful phytoestrogens, present in the skins of grapes and other plant foods and wine, which demonstrate a broad spectrum of pharmacological and therapeutic health benefits. Phytoestrogens are naturally occurring plant-derived nonsteroidal compounds that are functionally and structurally similar to steroidal estrogens, such as estradiol, produced by the body. Various studies, reviewed herein, have demonstrated the health benefits of phytoestrogens in addressing climacteric syndrome including vasomotor symptoms and postmenopausal health risks, as well as their anticarcinogenic, neuroprotective and cardioprotective activities and prostate health and bone formation promoting properties. Conventional HRT drugs have been demonstrated to cause serious adverse effects including stroke and gallbladder disease, as well as endometrial, uterine and breast cancers. Recent research demonstrates that trans-resveratrol binds to human estrogen receptors and increases estrogenic activity in the body. We investigated the effects of protykin, a standardized extract of trans-resveratrol from Polygonum cuspidatum, on cardioprotective function, the incidence of reperfusion-induced arrhythmias and free radical production in isolated ischemic/reperfused rat hearts. The rats were orally treated with two different daily doses of protykin for 3 weeks. Coronary effluents were measured for oxygen free radical production by electron spin resonance (ESR) spectroscopy in treated and drug-free control groups. In rats treated with 50 and 100 mg/kg of protykin, the incidence of reperfusion-induced ventricular fibrillation was reduced from its control value of 83% to 75% (p < 0.05) and 33% (p < 0.05), respectively. Protykin was seen to possess cardioprotective effects against reperfusion-induced arrhythmias through its ability to reduce or remove the reactive oxygen species in ischemic/reperfused myocardium. Taken together, these data suggest that trans-resveratrol supplementation may be a potential alternative to conventional HRT for cardioprotection and osteoporosis prevention and may confer other potential health benefits in women.

    Topics: Animals; Anthocyanins; Anticarcinogenic Agents; Antioxidants; Dose-Response Relationship, Drug; Estrogens, Non-Steroidal; Female; Free Radicals; Heart Diseases; Humans; Isoflavones; Phytoestrogens; Plant Preparations; Proanthocyanidins; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Resveratrol; Stilbenes; Ventricular Fibrillation

2001
Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes.
    Cardiovascular research, 2000, Aug-18, Volume: 47, Issue:3

    The major objective of the present study was to examine the cardioprotective effect of resveratrol, an antioxidant presents in red wines, in the rat after ischemia and ischemia-reperfusion (I-R).. The left main coronary artery was occluded for 30 or 5 min followed by a 30-min reperfusion in anesthetized rats. Animals were preinfused with and without resveratrol before occlusion and the severity of ischemia- and I-R-induced arrhythmias and mortality were compared.. Resveratrol pretreatment had no effect on ischemia-induced arrhythmias nor on mortality. In contrast, a dramatic protective effects were observed against I-R-induced arrhythmias and mortality. Resveratrol pretreatment both reduced the incidence and duration of ventricular tachycardia (VT) and ventricular fibrillation (VF). During the same period, resveratrol pretreatment also increased nitric oxide (NO) and decreased lactate dehydrogenase levels in the carotid blood.. Resveratrol is a potent antiarrhythmic agent with cardioprotective properties in I-R rats. The cardioprotective effects of resveratrol in the I-R rats may be correlated with its antioxidant activity and upregulation of NO production.

    Topics: Analysis of Variance; Animals; Antioxidants; Blood Pressure; Chi-Square Distribution; Free Radical Scavengers; Heart Rate; L-Lactate Dehydrogenase; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Nitric Oxide; Rats; Rats, Sprague-Dawley; Resveratrol; Statistics, Nonparametric; Stilbenes; Tachycardia, Ventricular; Ventricular Fibrillation

2000
chemdatabank.com